The Filing Desk

ImmunityBio

IBRX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

IBRX · Last close · November 13, 2026
$6.02
Value ImmunityBio yourself

ImmunityBio's revenue rose 668.3% to $113 million in fiscal 2025. Its operating margin was −226.0%, up from −2,334.2% a year earlier. Free cash flow was −$309 million. The diluted share count rose 31.3%.

IMMUNITYBIO, INC. Latest fiscal year ended December 31, 2025 10-K filed February 23, 2026 · 0001326110-26-000030 Updated
Revenue
$113M
668.3%
Operating margin
−226.0%
2108.2 pts
Net income
−$351M
 
Free cash flow
−$309M
 
Return on equity
—
 
Market cap
$6.4B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What ImmunityBio does

ImmunityBio is a biotechnology company that develops treatments to help the immune system fight cancer and some infectious diseases. Its first and only approved product, ANKTIVA, is a protein that activates certain immune cells. It is used together with the standard BCG treatment for adults with non-muscle invasive bladder cancer that no longer responds to BCG.

ANKTIVA is approved in the United States, the United Kingdom and Saudi Arabia, and received conditional approval in the European Union in February 2026. In Saudi Arabia it also has conditional approval for use with other drugs in a form of metastatic lung cancer. The company is trying to win approval for more uses, including bladder tumors with papillary growths and lung cancer.

It has many other candidates in development, grouped under a platform it calls Cancer BioShield. The company has a financing agreement with Oberland, called the RIPA, under which it must make payments, and it also owes money on a promissory note to a related party.

Its biggest risks, as it describes them

  • It has a single approved product and limited experience selling medicines.
  • Payment obligations under its RIPA financing agreement could hurt its finances and its ability to raise money.
  • The RIPA includes operating limits and default events that could keep it from pursuing opportunities.
  • It may not win approval of ANKTIVA for more uses or sell it successfully in new markets.
  • Its reliance on third parties and the cost of raising money through shares, debt or licenses.
From ImmunityBio's annual report on Form 10-K, filed February 23, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

ImmunityBio lost money in fiscal 2025: a net loss of $351 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments317107266150243
Debt incl. finance leases—67357700
Net debt (negative means net cash)—566310−150−242
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−22.2x−5.5x−2.8x−3.0x−4.2x
Current ratio0.9x0.3x5.0x3.4x5.1x
Quick ratio0.9x0.3x5.0x3.2x5.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project ImmunityBio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought ImmunityBio shares on the open market, and 3 insiders sold $8.4 million, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 2, 2026Cheryl CohenDirectorSold plan131,210$9.50$1.2 millionForm 4
Jul 1, 2026Christobel SeleckyDirectorSold plan159,478$9.02$1.4 millionForm 4
Jun 30, 2026Christobel SeleckyDirectorSold plan1,000$9.00$9,000Form 4
Jun 29, 2026Christobel SeleckyDirectorSold plan95,722$9.01$862,455Form 4
Jun 24, 2026Barry J. SimonDirectorSold plan25,000$7.88$197,000Form 4
Jun 4, 2026Barry J. SimonDirectorSold plan23,033$7.18$165,377Form 4
Feb 24, 2026Barry J. SimonDirectorSold plan75,000$12.01$900,750Form 4
Feb 23, 2026Barry J. SimonDirectorSold plan165,000$10.25$1.7 millionForm 4
Feb 23, 2026Christobel SeleckyDirectorSold plan25,000$10.00$250,000Form 4
Feb 20, 2026Barry J. SimonDirectorSold plan10,000$9.25$92,500Form 4
Jan 20, 2026Barry J. SimonDirectorSold plan151,967$7.20$1.1 millionForm 4
Jan 20, 2026Christobel SeleckyDirectorSold plan25,000$7.51$187,750Form 4
The latest 12 of 13 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 94 of 93 of 9
Rule of 40−63,722.0%−429.5%395.8%
Altman Z''−21.46−33.14−24.85
Accruals ratio−49.9%−5.0%−10.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassFail
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin roseFailFailFail
Revenue rose relative to assetsPassPassPass
F-score4 of 94 of 93 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put ImmunityBio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
ImmunityBioFY25668.3%−226.0%−272.6%——3
Monte Rosa TherapeuticsFY2563.5%−43.8%−22.2%———Compare
XencorFY2513.7%−141.3%−110.1%−19.9%—3Compare
Beam TherapeuticsFY25120.0%−274.6%−257.6%———Compare
CytokineticsFY25376.6%−695.4%−607.5%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue0002110115113
Revenue growth−81.4%2.3%4.4%4,585.1%−72.5%54.4%−74.3%159.2%2,270.6%668.3%
Gross profit——————0115112
Research and development294256112140196248232190—
Operating income−124−99−98−156−221−330−351−362−344−256
Net income−121−96−96−158−222−347−417−583−414−351
Diluted EPS (US$)−1.47−1.20−1.22−0.43−0.59−0.89−1.04−1.15−0.62−0.38
Diluted shares (millions)828179366377389400509700920
Cash flow
Cash from operations−39−49−63−152−172−274−338−367−391−305
Capital expenditure735134234783174
Free cash flow−45−84−76−156−173−308−416−397−398−309
Dividends paid0000000000
Share buybacks161502000000
Acquisitions0000000010
Stock-based compensation743723325740493437
Balance sheet at fiscal year end
Cash and short-term investments1991287411296317107266150243
Debt incl. finance leases——————67357700
Total assets318250182143221469362504383502
Total liabilities243236223407138121,0908711,002
Shareholders' equity293219146121−120−242−447−587−489−500
Margins and ratios
Gross margin——————100.0%100.0%100.0%99.3%
Operating margin−282,954.5%−220,266.7%−209,338.3%−7,095.9%−36,509.1%−35,361.9%−146,374.2%−58,239.6%−2,334.2%−226.0%
Net margin−274,565.9%−214,273.3%−204,736.2%−7,165.2%−36,669.6%−37,129.6%−173,569.6%−93,761.4%−2,804.8%−310.2%
Free cash flow margin−102,620.4%−185,766.7%−162,729.8%−7,102.4%−28,660.0%−32,974.5%−173,196.2%−63,881.2%−2,700.1%−272.6%
Rule of 40 (growth + FCF margin)−102,701.8%−185,764.4%−162,725.3%−2,517.3%−28,732.5%−32,920.1%−173,270.5%−63,722.0%−429.5%395.8%
Return on capital——————————
Return on equity−37.2%−37.6%−52.8%−118.3%——————
Return on assets−35.3%−34.0%−44.5%−97.1%−121.7%−100.5%−100.2%−134.6%−93.2%−79.4%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: ImmunityBio's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with ImmunityBio.